As of the latest Form 4 filed Jul 1, 2026.
What TriSalus Life Sciences Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 18 most recent filings for TLSI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | Szela Mary T CEO and President | AAward | +3.99K | $3.87 | $15.4K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Marshak Richard Chief Commercial Officer | AAward | +561.00 | $3.87 | $2.17K | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Marshall Richard Henry Chief Medical Officer | AAward | +60.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-20 | 2025-07-31 | Frankenius Equity AB 10% owner | CConvert | +759K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-17 | Szela Mary T CEO and President | SSale | −15.9K | $3.85 | $61.4K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-16 | Devlin Jodi Chief of Clinical Operations | SSale | −273.00 | $4.12 | $1.12K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-16 | Cox Bryan F. Chief of Research | SSale | −579.00 | $4.12 | $2.39K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-16 | Marshak Richard Chief Commercial Officer | SSale | −419.00 | $4.12 | $1.73K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-16 | Stevens Jennifer Chief Regulatory Officer | SSale | −774.00 | $4.12 | $3.19K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-12 | Devlin Jodi Chief of Clinical Operations | SSale | −1.77K | $4.09 | $7.25K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-12 | Cox Bryan F. Chief of Research | SSale | −1.47K | $4.09 | $6.00K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-12 | Marshak Richard Chief Commercial Officer | SSale | −1.59K | $4.09 | $6.50K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-12 | Stevens Jennifer Chief Regulatory Officer | SSale | −1.55K | $4.09 | $6.35K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-11 | Devlin Jodi Chief of Clinical Operations | SSale | −1.16K | $4.13 | $4.80K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-11 | Cox Bryan F. Chief of Research | SSale | −1.14K | $4.13 | $4.70K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-11 | Marshak Richard Chief Commercial Officer | SSale | −1.45K | $4.13 | $5.98K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-11 | Stevens Jennifer Chief Regulatory Officer | SSale | −1.20K | $4.13 | $4.97K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-11 | Szela Mary T CEO and President | SSale | −4.36K | $4.13 | $18.0K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TLSI’s full analysis or the market-wide insider trading feed. The tabs above jump to TLSI’s other SEC data.
Source: SEC Form 4 filings for TLSI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.